Daniel Baker, M.D., will join Cue Biopharma’s executive team as interim chief development officer (CDO), effective Monday, November 25, 2024Anish ...

Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...

In its lawsuit, the company argued that HRSA has wrongfully interpreted a federal law concerning the use of rebates in the 340B Drug Pricing Program. J&J recently sought to change payment terms for ...

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...